235 related articles for article (PubMed ID: 35948138)
1. Recent advances in natural products as potential inhibitors of dengue virus with a special emphasis on NS2b/NS3 protease.
Saqallah FG; Abbas MA; Wahab HA
Phytochemistry; 2022 Oct; 202():113362. PubMed ID: 35948138
[TBL] [Abstract][Full Text] [Related]
2. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.
Lin KH; Ali A; Rusere L; Soumana DI; Kurt Yilmaz N; Schiffer CA
J Virol; 2017 May; 91(10):. PubMed ID: 28298600
[TBL] [Abstract][Full Text] [Related]
3. Investigating Lycotoxin-An1a (An1a), a defense antiviral peptide from Alopecosa nagpag venom as prospective anti-dengue agent against DENV-2 NS2B-NS3 protease.
Purohit P; Barik D; Dansana J; Meher BR
Comput Biol Chem; 2024 Feb; 108():108005. PubMed ID: 38157660
[TBL] [Abstract][Full Text] [Related]
4. In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease.
Dwivedi VD; Tripathi IP; Mishra SK
J Vector Borne Dis; 2016; 53(2):156-61. PubMed ID: 27353586
[TBL] [Abstract][Full Text] [Related]
5. Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection.
Huang Y-J; Cheng T-L; Wang Y-T; Chen C-S; Leu Y-L; Chang C-S; Ho C-H; Chao S-W; Li C-T; Chuang C-H
J Virol; 2024 Apr; 98(4):e0125823. PubMed ID: 38546211
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the inhibitory potency of anti-dengue phytocompounds against DENV-2 NS2B-NS3 protease: virtual screening, ADMET profiling and molecular dynamics simulation investigations.
Purohit P; Barik D; Agasti S; Panda M; Meher BR
J Biomol Struct Dyn; 2024 Apr; 42(6):2990-3009. PubMed ID: 37194462
[TBL] [Abstract][Full Text] [Related]
7. Targeting the DENV NS2B-NS3 protease with active antiviral phytocompounds: structure-based virtual screening, molecular docking and molecular dynamics simulation studies.
Purohit P; Sahoo S; Panda M; Sahoo PS; Meher BR
J Mol Model; 2022 Oct; 28(11):365. PubMed ID: 36274116
[TBL] [Abstract][Full Text] [Related]
8. A Critical Observation on the Design and Development of Reported Peptide Inhibitors of DENV NS2B-NS3 Protease in the Last Two Decades.
Murtuja S; Shilkar D; Sarkar B; Sinha BN; Jayaprakash V
Mini Rev Med Chem; 2022; 22(8):1108-1130. PubMed ID: 34720077
[TBL] [Abstract][Full Text] [Related]
9. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay.
Yang CC; Hsieh YC; Lee SJ; Wu SH; Liao CL; Tsao CH; Chao YS; Chern JH; Wu CP; Yueh A
Antimicrob Agents Chemother; 2011 Jan; 55(1):229-38. PubMed ID: 20937790
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.
Takagi Y; Matsui K; Nobori H; Maeda H; Sato A; Kurosu T; Orba Y; Sawa H; Hattori K; Higashino K; Numata Y; Yoshida Y
Bioorg Med Chem Lett; 2017 Aug; 27(15):3586-3590. PubMed ID: 28539222
[TBL] [Abstract][Full Text] [Related]
11. Discovery of antiviral molecules for dengue: In silico search and biological evaluation.
Cabarcas-Montalvo M; Maldonado-Rojas W; Montes-Grajales D; Bertel-Sevilla A; Wagner-Döbler I; Sztajer H; Reck M; Flechas-Alarcon M; Ocazionez R; Olivero-Verbel J
Eur J Med Chem; 2016 Mar; 110():87-97. PubMed ID: 26807547
[TBL] [Abstract][Full Text] [Related]
12. Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells.
Wu DW; Mao F; Ye Y; Li J; Xu CL; Luo XM; Chen J; Shen X
Acta Pharmacol Sin; 2015 Sep; 36(9):1126-36. PubMed ID: 26279156
[TBL] [Abstract][Full Text] [Related]
13. Structure activity relationship (SAR) and quantitative structure activity relationship (QSAR) studies showed plant flavonoids as potential inhibitors of dengue NS2B-NS3 protease.
Sarwar MW; Riaz A; Dilshad SMR; Al-Qahtani A; Nawaz-Ul-Rehman MS; Mubin M
BMC Struct Biol; 2018 Apr; 18(1):6. PubMed ID: 29673347
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and in-
Abdalsatar Abdalrazaq N; Ezleen Binti Kamarulzaman E
Arch Razi Inst; 2022 Apr; 77(2):843-852. PubMed ID: 36284983
[TBL] [Abstract][Full Text] [Related]
15. Repurposing of investigational cancer drugs: Early phase discovery of dengue virus NS2B/NS3 protease inhibitors.
Saleem HN; Kousar S; Jiskani AH; Sohail I; Faisal A; Saeed M
Arch Pharm (Weinheim); 2023 Nov; 356(11):e2300292. PubMed ID: 37582646
[TBL] [Abstract][Full Text] [Related]
16. Discovery of highly potent DENV NS2B-NS3 covalent inhibitors containing a phenoxymethylphenyl residue.
Cheng J; Feng S; Zhang Y; Ding T; Jiang H; Zhang Z; Wang J; Wang X; Cheng M
Biochem Biophys Res Commun; 2022 Oct; 627():214-219. PubMed ID: 36058105
[TBL] [Abstract][Full Text] [Related]
17. Synthetic peptide optimization improves the inhibition of dengue NS2B-NS3 protease and dengue replication in vitro.
Abdulrahman AY; Rothan HA; Khazali AS; Teoh TC; Daher AM; Yusof R
Acta Virol; 2019; 63(3):278-285. PubMed ID: 31507193
[TBL] [Abstract][Full Text] [Related]
18. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.
Tomlinson SM; Watowich SJ
Antiviral Res; 2011 Feb; 89(2):127-35. PubMed ID: 21185332
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR and molecular docking studies of peptide-hybrids as dengue virus NS2B/NS3 protease inhibitors.
Jitonnom J; Meelua W; Tue-Nguen P; Saparpakorn P; Hannongbua S; Chotpatiwetchkul W
Chem Biol Interact; 2024 Jun; 396():111040. PubMed ID: 38735453
[TBL] [Abstract][Full Text] [Related]
20. An Antiviral Peptide from
Ji M; Zhu T; Xing M; Luan N; Mwangi J; Yan X; Mo G; Rong M; Li B; Lai R; Jin L
Toxins (Basel); 2019 Oct; 11(10):. PubMed ID: 31658707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
